LY3295668 Erbumine

Erbumine · Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LY3295668 Erbumine, covering 2026-04-21 to 2026-04-21. Get the full timeline:

Most recent: Clinical Trial Update: A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma [Phase 1]